Study guide

4.3 Histopathological Grading (ISUP Gleason) & Staging

FEBU Part 1 Written European Board of Urology

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice

2 Chapter 2: Genitourinary Anatomy & Renal Physiology

2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance

3 Chapter 3: Urological Pharmacology & Diagnostic Imaging

3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine

4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification

4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging

5 Chapter 5: Prostate Cancer: Localized & Advanced Management

5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)

6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)

6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy

7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma

7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)

8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms

8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas

9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer

9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy

10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms

10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO

11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology

11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation

12 Chapter 12: Urolithiasis: Evaluation & Medical Management

12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy

13 Chapter 13: Endourology & Interventional Stone Management

13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety

14 Chapter 14: Infections, Andrology & Male Infertility

14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery

15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation

15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation

4.3 Histopathological Grading (ISUP Gleason) & Staging

Key Takeaways Explain This Topic AI

ISUP Grade Groups complement the reported Gleason score: GG1=3+3, GG2=3+4, GG3=4+3, GG4=8 and GG5=9–10. On needle biopsy, a minor higher-grade component is incorporated into the score; prostatectomy uses different minor-pattern rules.

Cribriform architecture and intraductal carcinoma are adverse histological findings. EAU strongly recommends excluding patients with either finding on biopsy from active surveillance, even with otherwise favourable Grade Group2 disease.

EAU clinical T-stage is based on DRE; report MRI staging separately. Non-palpable needle-biopsy cancer is cT1c, palpable organ-confined cancer cT2, extracapsular disease cT3a and seminal-vesicle involvement cT3b. Microscopic bladder-neck invasion is a pathological pT3a criterion.

EAU2026 localized risk groups combine PSA and Grade Group within cT1–2. cT2c alone is not high risk; PSA>20 or GG4–5 defines high-risk localized disease. Low-risk and favourable intermediate-risk disease need no routine additional metastatic staging.

The prospective proPSMA trial demonstrated that Gallium-68 PSMA-PET/CT achieves 27% greater diagnostic accuracy (92% vs 65%), superior sensitivity (85% vs 38%), and lower radiation dose compared to conventional CT and bone scan in high-risk prostate cancer, establishing PSMA-PET as the premier molecular staging tool.

Last updated: November 2026

Histopathological Grading (ISUP Gleason) & Staging

Accurate oncological staging and histopathological grading form the cornerstone of clinical decision-making in prostate cancer. Following tissue acquisition via targeted biopsy with perilesional sampling or systematic biopsy, precise risk stratification dictates whether a patient is a candidate for active surveillance, nerve-sparing radical prostatectomy, dose-escalated radiotherapy with androgen deprivation therapy, or multimodal systemic therapy.

The Evolution of Histopathological Grading: From Gleason to ISUP Grade Groups

In 1966, Donald Gleason devised a histological grading system based solely on glandular architectural patterns (patterns 1 through 5) under low-power magnification, deliberately ignoring cytological atypia. The classical Gleason Score was generated by summing the primary (most prevalent) pattern and secondary (second most prevalent) pattern, creating a theoretical score ranging from 2 to 10.

Over subsequent decades, major revisions by the International Society of Urological Pathology (ISUP) in 2005 and 2014 fundamentally altered prostate cancer grading:

Patterns 1 and 2 are not assigned in contemporary needle biopsy reporting; modern assessment uses patterns3–5.

Ill-defined glands, fused glands, and cribriform architectures were reclassified definitively as Gleason Pattern 4 .

Consequently, the lowest score assigned on needle biopsy became Gleason 3+3=6 .

The 2014/2016 ISUP Grade Group Classification

Reporting Gleason score 6 on a scale of 2 to 10 created substantial psychological distress for patients, who intuitively believed they had an intermediate, mid-tier cancer. Moreover, the historical Gleason 7 designation failed to distinguish between tumors dominated by low-grade glands (Gleason 3+4=7) versus those dominated by aggressive pattern 4 glands (Gleason 4+3=7).

To resolve these limitations, ISUP established the ISUP Grade Group system (subsequently endorsed by the World Health Organization [WHO] in 2016 and 2022): ISUP GRADE GROUP CLASSIFICATION

  • ├── Grade Group 1 ──> Gleason 3+3 = 6 (Indolent, discrete glands; ~0% metastatic potential)
  • ├── Grade Group 2 ──> Gleason 3+4 = 7 (Predominantly pattern 3 with <50% pattern 4)
  • ├── Grade Group 3 ──> Gleason 4+3 = 7 (Predominantly pattern 4 with >50% pattern 4)
  • ├── Grade Group 4 ──> Gleason 8 (4+4, 3+5, or 5+3; high-risk biology)
  • └── Grade Group 5 ──> Gleason 9–10 (4+5, 5+4, or 5+5; dedifferentiated sheets/comedonecrosis)
  • Key Pathological Distinctions Between Grade Groups

ISUP Grade Group 1 (Gleason 3+3=6) : Composed purely of discrete, well-formed, individual malignant glands. It carries essentially zero potential for lymph node or distant metastasis when strictly organ-confined. Patients with Grade Group 1 disease are the primary candidates for active surveillance .

ISUP Grade Group 2 (Gleason 3+4=7) vs. ISUP Grade Group 3 (Gleason 4+3=7) : This distinction represents a critical clinical pivot point. While both sum to 7, Grade Group 3 harbors a predominance (>50%) of high-grade pattern 4 glands . Patients with Grade Group 3 exhibit a 2- to 3-fold higher rate of biochemical recurrence, a significantly shorter metastasis-free survival, and an increased risk of cancer-specific death compared to Grade Group 2.

Minor Higher-Grade Patterns : Specimen type matters. On needle biopsy , incorporate a minor higher-grade component into the score; when three patterns are present, combine the most prevalent with the highest, irrespective of its amount. A core with predominant pattern3, pattern4 and <5% pattern5 is 3+5=8 (GG4) . In a prostatectomy with predominant patterns3 and4, a minor pattern5 below5% can instead be reported separately alongside 3+4=7.

Critical Adverse Histological Variants: Cribriform Pattern & IDC-P

Beyond basic Grade Group assignment, pathology reports must evaluate two adverse architectural entities that carry profound clinical implications:

1. Large Cribriform Architecture (Gleason Pattern 4)

Cribriform pattern 4 is characterized by solid islands of malignant epithelial cells perforated by multiple, well-delineated, rounded lumina without intervening stroma, resembling a perforated sieve:

Molecular Biology : Strongly correlated with genomic instability, characterized by frequent PTEN deletion, SPOP mutations, and high genomic copy number alterations.

Clinical Impact : Independent predictor of post-prostatectomy biochemical recurrence, bone metastasis, and cancer-specific mortality. Its presence, even in low-volume Grade Group 2 disease, is an EAU exclusion criterion for active surveillance when identified on biopsy (strong recommendation).

2. Intraductal Carcinoma of the Prostate (IDC-P)

IDC-P is defined by the malignant proliferation of high-grade neoplastic epithelial cells within pre-existing, native prostatic acini and ducts, with preservation of the underlying basal cell layer (demonstrated immunohistochemically by p63 or high-molecular-weight cytokeratin [HMWCK] positivity):

Morphology : Displays marked nuclear enlargement (at least 6-fold larger than normal), solid or dense cribriform architecture, and characteristic central comedonecrosis .

Distinction from High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) : HGPIN also retains basal cells, but lacks marked ductal expansion, dense cribriform architecture, and comedonecrosis. HGPIN on biopsy does not alter treatment pathways, whereas IDC-P represents retrograde intraductal spread of advanced, highly dedifferentiated invasive carcinoma.

Genomic & Therapeutic Significance : Strongly associated with germline and somatic mutations in DNA homologous recombination repair (HRR) genes, predominantly BRCA2 , ATM , and CDK12 . Patients harboring IDC-P experience rapid progression to castration resistance and poor survival. Active surveillance is strictly contraindicated in the presence of IDC-P.

TNM Staging Classification (UICC / AJCC 8th Edition)

The current EAU guideline uses TNM8. Clinical T-stage is based on DRE , with MRI findings reported separately. Pathological stage is determined from the surgical specimen; do not substitute microscopic pathological findings into a clinical T-category.

Primary Tumor (T Category)

cT1 : Clinically inapparent, non-palpable tumor:

cT1a : Tumor incidental histological finding in <= 5% of tissue resected (e.g., transurethral resection of prostate [TURP] for BPH).

cT1b : Tumor incidental histological finding in > 5% of tissue resected.

cT1c : Tumor identified by needle biopsy prompted by elevated serum PSA.

cT2 : Palpable tumor confined within the prostate:

cT2a : Involves one-half of one lobe or less.

cT2b : Involves more than one-half of one lobe, but not both lobes.

cT2c : Involves both prostatic lobes.

cT3 : Tumor extends palpably through the prostatic capsule (locally advanced):

cT3a : Palpable extracapsular extension (unilateral or bilateral).

cT3b : Tumor invades one or both seminal vesicles.

cT4 : Tumor is fixed or invades adjacent anatomical structures other than seminal vesicles: external sphincter, rectum, levator ani muscles, or pelvic wall.

Pathological distinction: Organ-confined cancer after prostatectomy is pT2 , without pT2a/b/c substages. Extraprostatic extension or microscopic bladder-neck invasion is pT3a ; seminal-vesicle invasion is pT3b.

Regional Lymph Nodes (N Category)

Regional lymph nodes are defined strictly as nodes situated within the true pelvis below the bifurcation of the common iliac arteries :

  • Hypogastric (internal iliac)
  • Obturator
  • External iliac
  • Presacral and sacral promontory nodes LYMPH NODE METASTASIS CATEGORIZATION
  • ├── Below Common Iliac Bifurcation (Internal/External Iliac, Obturator, Presacral) ──> N1 (Regional)
  • └── Non-regional (Common Iliac, Retroperitoneal/Para-aortic, Inguinal) ──> M1a (Distant)

Caution

Critical Exam Pitfall : Metastasis to common iliac, para-aortic, paracaval, inguinal, or supraclavicular lymph nodes is categorized as distant metastatic disease (M1a) , NOT regional nodal involvement (N1).

Distant Metastasis (M Category)

M0 : No distant metastasis.

M1 : Distant metastasis present:

M1a : Non-regional lymph node metastasis (common iliac, retroperitoneal, mediastinal, supraclavicular).

M1b : Bone metastasis (most common distant site; classically osteoblastic / sclerotic).

M1c : Other distant anatomical sites with or without bone disease (lung, liver, brain, adrenal glands).

EAU Risk Stratification for Localized Prostate Cancer

Use the EAU2026 Table4.3 definitions. Localized groups apply within cT1–2; clinical T-stage comes from DRE. A higher-risk PSA or grade takes precedence: EAU2026 RISK GROUPS

  • ├── LOW: GG1 AND PSA <10 AND cT1–2
  • ├── FAVOURABLE INTERMEDIATE: cT1–2, with either
  • │ ├── GG2 AND PSA <10
  • │ └── GG1 AND PSA 10–20
  • ├── UNFAVOURABLE INTERMEDIATE: cT1–2, PSA <=20, with either
  • │ ├── GG2 AND PSA 10–20
  • │ └── GG3
  • ├── HIGH LOCALIZED: GG4–5 OR PSA >20, with cT1–2
  • └── LOCALLY ADVANCED: cT3–4 and/or cN+, any PSA or GG

Low Risk: GG1, PSA<10 and cT1–2. Assess surveillance or watchful waiting according to life expectancy and other clinical factors.

Intermediate Risk: Distinguish favourable GG2/PSA<10 or GG1/PSA10–20 from unfavourable GG2/PSA10–20 or GG3. These are EAU definitions; a positive-core percentage rule from another classification should not be substituted for them.

High Risk: PSA>20 or GG4–5. cT2c alone is no longer an independent high-risk criterion in the current table. It remains an organ-confined clinical stage.

Locally Advanced: cT3–4 and/or regional nodal involvement, regardless of PSA or grade. Risk grouping helps guide management but does not assign a universal five-year metastasis probability to every patient.

Primary Staging Modalities and Molecular Imaging Evidence

The necessity for systemic metastatic staging depends on the assigned EAU risk group:

Staging Guidelines by Risk Category

Low-Risk and Favourable Intermediate-Risk Disease : EAU strongly recommends no routine additional staging imaging . This concerns metastatic screening, not the pre-biopsy MRI already used for diagnosis/local information.

Unfavourable Intermediate Risk : Offer PSMA-PET/CT if available, or at least cross-sectional abdominopelvic imaging plus a bone scan ( weak recommendation).

High-Risk Localized or Locally Advanced Disease : Perform metastatic screening with PSMA-PET/CT if available, or at least cross-sectional abdominopelvic imaging and bone scintigraphy ( strong recommendation).

Conventional Imaging vs. PSMA-PET/CT

Conventional Staging : Consists of contrast-enhanced CT of the abdomen/pelvis (or mpMRI of the pelvis) combined with whole-body technetium-99m (99mTc) bone scintigraphy. Conventional CT relies purely on anatomical size criteria (short-axis nodal diameter >= 8–10 mm) and has poor sensitivity (35–40%) for micrometastatic nodal disease. Bone scans detect osteoblastic remodeling, exhibiting high false-positive rates from trauma, arthritis, and degenerative joint disease.

Prostate-Specific Membrane Antigen (PSMA) PET/CT : PSMA is a 750-amino acid type II transmembrane glycoprotein overexpressed 100- to 1,000-fold in >90% of prostate adenocarcinomas. Positron emission tomography using radiolabeled small-molecule PSMA ligands—primarily Gallium-68 (68Ga-PSMA-11) and Fluorine-18 (18F-DCFPyL / 18F-PSMA-1007) —improves detection of nodal and distant disease. Small metastases below PET resolution can still be missed; a negative scan does not exclude microscopic nodal involvement.

Landmark Staging Evidence: The proPSMA Trial (Lancet 2020)

The prospective, multicentre randomized proPSMA study evaluated 302 patients with newly diagnosed high-risk localized prostate cancer scheduled for curative-intent surgery or radiation. Patients were randomized 1:1 to either conventional imaging (contrast CT + bone scan) versus 68Ga-PSMA-11 PET/CT:

Diagnostic Accuracy : PSMA-PET/CT demonstrated 27% greater absolute accuracy than conventional imaging ( 92% vs 65% , p < 0.0001) for detecting pelvic nodal and distant metastases.

Sensitivity and Specificity : PSMA-PET/CT showed vastly superior sensitivity ( 85% vs 38% ) and higher specificity ( 98% vs 91% ).

Radiation Dose : PSMA-PET/CT delivered less than half the radiation exposure of conventional imaging ( 8.4 mSv vs 19.2 mSv ).

Equivocal Findings : Equivocal or uncertain imaging reports were significantly reduced ( 7% with PSMA-PET vs 23% with conventional imaging ).

Treatment Impact : First-line imaging changed planned management in 28% with PSMA-PET/CT versus 15% with conventional imaging . This establishes an effect on treatment planning, not proof that every imaging-driven change improves survival.

Note

While EAU guidelines endorse PSMA-PET/CT as superior to conventional imaging for primary staging in high-risk disease, clinicians must recognize the phenomenon of stage migration (the Will Rogers effect) . PSMA-PET detects low-volume oligometastatic lesions that were previously occult on CT/bone scans. Randomized prospective trials evaluating whether treating these micro-metastases improves overall survival are ongoing.

EAU Risk Groups Classification for Localized Prostate Cancer

  • EAU2026 Risk Group PSA / Grade Logic Clinical Stage Routine Metastatic Staging
  • Low GG1 AND PSA<10 cT1–2 No additional staging imaging
  • Favourable intermediate GG2/PSA<10 OR GG1/PSA10–20 cT1–2 No additional staging imaging

Unfavourable intermediate GG2/PSA10–20 OR GG3, provided PSA≤20 cT1–2 PSMA-PET/CT if available, otherwise abdominopelvic CT/MRI plus bone scan (weak)

High localized GG4–5 OR PSA>20 cT1–2 PSMA-PET/CT if available, otherwise abdominopelvic CT/MRI plus bone scan (strong)

Locally advanced Any PSA / GG cT3–4 and/or cN+ PSMA-PET/CT if available, otherwise abdominopelvic CT/MRI plus bone scan (strong)